Calcipotriene Betamethasone Dipropionate Aerosol Foam in the Treatment of Plaque Psoriasis: A Review of the Literature

References

• Parisi R Symmons DP Griffiths CE et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J. Invest. Dermatol.133 (2), 377–385 (2013).
   PubMed Web of Science ®Google Scholar
• World Health Organization: Global report on psoriasis (2016). http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf.
   Google Scholar
• Korman NJ Zhao Y Pike J Roberts J . Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin. Exp. Dermatol.41 (5), 514–521 (2016).
   PubMed Web of Science ®Google Scholar
• Kirby B Richards HL Mason DL Fortune DG Main CJ Griffiths CE . Alcohol consumption and psychological distress in patients with psoriasis. Br. J. Dermatol.158 (1), 138–140 (2008).
   PubMed Web of Science ®Google Scholar
• Gelfand JM Troxel AB Lewis JD et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch. Dermatol.143 (12), 1493–1499 (2007).
   PubMed Web of Science ®Google Scholar
• Abuabara K Azfar RS Shin DB Neimann AL Troxel AB Gelfand JM . Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br. J. Dermatol.163 (3), 586–592 (2010).
   PubMed Web of Science ®Google Scholar
• Neimann AL Shin DB Wang X Margolis DJ Troxel AB Gelfand JM . Prevalence of cardiovascular risk factors in patients with psoriasis. J. Am. Acad. Dermatol.55 (5), 829–835 (2006).
   PubMed Web of Science ®Google Scholar
• Gottlieb A Korman NJ Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J. Am. Acad. Dermatol.58 (5), 851–864 (2008).
   PubMed Web of Science ®Google Scholar
• Najarian DJ Gottlieb AB . Connections between psoriasis and Crohn's disease. J. Am. Acad. Dermatol.48 (6), 805–821 ; quiz 822–804 (2003).
   PubMed Web of Science ®Google Scholar
• Davidovici BB Sattar N Prinz J et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J. Invest. Dermatol.130 (7), 1785–1796 (2010).
   PubMed Web of Science ®Google Scholar
• Armstrong AW Voyles SV Armstrong EJ Fuller EN Rutledge JC . Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J. Dermatol. Sci.63 (1), 1–9 (2011).
   PubMed Web of Science ®Google Scholar
• Alexander H Nestle FO . Pathogenesis and immunotherapy in cutaneous psoriasis: what can rheumatologists learn?Curr. Opin. Rheumatol.29 (1), 71–78 (2017).
   PubMed Web of Science ®Google Scholar
• American Academy of Dermatology Work G , MenterAKormanNJet al.Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J. Am. Acad. Dermatol.65 (1), 137–174 (2011).
   PubMed Web of Science ®Google Scholar
• Menter A Gottlieb A Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J. Am. Acad. Dermatol.58 (5), 826–850 (2008).
   PubMed Web of Science ®Google Scholar
• Bewley A Page B . Maximizing patient adherence for optimal outcomes in psoriasis. J. Eur. Acad. Dermatol. Venereol.25 (Suppl. 4), 9–14 (2011).
   PubMed Web of Science ®Google Scholar
• Lind M Nielsen KT Schefe LH et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol. Ther. (Heidelb.)6 (3), 413–425 (2016).
   PubMed Web of Science ®Google Scholar
• Milde P Hauser U Simon T et al. Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J. Invest. Dermatol.97 (2), 230–239 (1991).
   PubMed Web of Science ®Google Scholar
• Jensen T Sorensen S Solvsten H Kragballe K . The vitamin D3 receptor and retinoid X receptors in psoriatic skin: the receptor levels correlate with the receptor binding to DNA. Br. J. Dermatol.138 (2), 225–228 (1998).
   PubMed Web of Science ®Google Scholar
• Bartosik-Psujek H Tabarkiewicz J Pocinska K Stelmasiak Z Rolinski J . Immunomodulatory effects of vitamin D on monocyte-derived dendritic cells in multiple sclerosis. Mult. Scler.16 (12), 1513–1516 (2010).
   PubMedGoogle Scholar
• Gorman S Kuritzky LA Judge MA et al. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J. Immunol.179 (9), 6273–6283 (2007).
   PubMed Web of Science ®Google Scholar
• Boonstra A Barrat FJ Crain C Heath VL Savelkoul HF O'garra A . 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J. Immunol.167 (9), 4974–4980 (2001).
   PubMed Web of Science ®Google Scholar
• Chen ML Perez A Sanan DK Heinrich G Chen TC Holick MF . Induction of vitamin D receptor mRNA expression in psoriatic plaques correlates with clinical response to 1,25-dihydroxyvitamin D3. J. Invest. Dermatol.106 (4), 637–641 (1996).
   PubMed Web of Science ®Google Scholar
• Colin EM Asmawidjaja PS Van Hamburg JP et al. 1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum.62 (1), 132–142 (2010).
   PubMedGoogle Scholar
• Uva L Miguel D Pinheiro C et al. Mechanisms of action of topical corticosteroids in psoriasis. Int. J. Endocrinol.2012, 561018 (2012).
   PubMed Web of Science ®Google Scholar
• Mcmanus R . Mechanisms of steroid action and resistance in inflammation and disease. J. Endocrinol.178 (1), 1–4 (2003).
   PubMedGoogle Scholar
• Ahluwalia A . Topical glucocorticoids and the skin--mechanisms of action: an update. Mediators Inflamm.7 (3), 183–193 (1998).
   PubMed Web of Science ®Google Scholar
• Barnes PJ . Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci. (Lond.)94 (6), 557–572 (1998).
   PubMed Web of Science ®Google Scholar
• Lovato P Norsgaard H Tokura Y Ropke MA . Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell-Th17 cell axis in psoriasis. J. Dermatol. Sci.81 (3), 153–164 (2016).
   PubMed Web of Science ®Google Scholar
• Huang X Tanojo H Lenn J Deng CH Krochmal L . A novel foam vehicle for delivery of topical corticosteroids. J. Am. Acad. Dermatol.53 (1 Suppl. 1), S26–S38 (2005).
   PubMed Web of Science ®Google Scholar
• Williams AC Barry BW . Skin absorption enhancers. Crit. Rev. Ther. Drug Carrier Syst.9 (3–4), 305–353 (1992).
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C Bang B Clonier F Lacour JP . Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments. J. Eur. Acad. Dermatol. Venereol.30 (11), 1951–1956 (2016).
   PubMed Web of Science ®Google Scholar
• Basse Lh OM Lacour Jp Queille-Roussel C . Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle. J. Invest. Dermatol.134 (S33), Abstract 192 (2014).
   Google Scholar
• Queille-Roussel C Olesen M Villumsen J Lacour JP . Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris. Clin. Drug Investig.35 (4), 239–245 (2015).
   PubMed Web of Science ®Google Scholar
• LEO Pharma . Enstilar® (calcipotriene and betamethasone dipropionate) foam: US prescribing information (2016).
   Google Scholar
• LEO Pharma . Enstilar® (calcipotriol/betamethasone dipropionate) cutaneous foam: UK summary of product characteristics (2016).
   Google Scholar
• Taraska V Tuppal R Olesen M Bang Pedersen C Papp K . A novel aerosol foam formulation of calcipotriol and betamethasone has no impact on HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris. J. Cutan. Med. Surg.20 (1), 44–51 (2016).
   PubMed Web of Science ®Google Scholar
• Koo J Tyring S Werschler WP et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--a randomized Phase II study. J. Dermatolog. Treat.27 (2), 120–127 (2016).
   PubMed Web of Science ®Google Scholar
• Lebwohl M Tyring S Bukhalo M et al. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, Phase II study. J. Clin. Aesthet. Dermatol.9 (2), 34–41 (2016).
   PubMedGoogle Scholar
• Leonardi C Bagel J Yamauchi P et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris--a randomized Phase III study (PSO-FAST). J. Drugs Dermatol.14 (12), 1468–1477 (2015).
   PubMed Web of Science ®Google Scholar
• Stein Gold L Villumsen J Rosen M . Calcipotriol plus betamethasone dipropionate aerosol foam is effective, independent of body mass index and the extent and severity of psoriasis. Dermatol. Ther. (Heidelb.)6 (4), 667–673 (2016).
   PubMed Web of Science ®Google Scholar
• Paul C Stein Gold L Cambazard F et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J. Eur. Acad. Dermatol. Venereol.31 (1), 119–126 (2017).
   PubMed Web of Science ®Google Scholar
• Paul C Leonardi C Menter A et al. Calcipotriol plus betamethasone dipropionate aerosol foam in patients with moderate-to-severe psoriasis: sub-group analysis of the PSO-ABLE study. Am. J. Clin. Dermatol.18 (3), 405–441 (2017).
   PubMed Web of Science ®Google Scholar
• Stein Gold L Lebwohl M Menter A Villumsen J Rosen M Koo J . Aerosol foam formulation of fixed combination calcipotriene plus betamethasone dipropionate is highly efficacious in patients with psoriasis vulgaris: pooled data from three randomized controlled studies. J. Drugs Dermatol.15 (8), 951–957 (2016).
   PubMed Web of Science ®Google Scholar
• Finlay AY Khan GK . Dermatology life quality index (DLQI)--a simple practical measure for routine clinical use. Clin. Exp. Dermatol.19 (3), 210–216 (1994).
   PubMed Web of Science ®Google Scholar
• Leonardi C Bagel J Yamauchi P et al. The aerosol foam formulation of the fixed combination calcipotriene plus betamethasone dipropionate improves the health-related quality of life in patients with psoriasis vulgaris: results from the randomized PSO-FAST study. J. Drugs Dermatol.15 (8), 981–987 (2016).
   PubMed Web of Science ®Google Scholar
• Pickard AS Gooderham M Hartz S Nicolay C . EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. J. Med. Econ.20 (1), 19–27 (2017).
   PubMed Web of Science ®Google Scholar
• Paul C Gold LS Cambazard F et al. More rapid improvement in quality of life with fixed combination calcipotriene plus betamethasone dipropionate aerosol foam versus topical suspension (PSO-ABLE study in patients with psoriasis vulgaris). J. Am. Acad. Dermatol.74 (5), AB260 (2016).
   Web of Science ®Google Scholar
• Housman TS Mellen BG Rapp SR Fleischer AB, Jr Feldman SR . Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis70 (6), 327–332 (2002).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB Ford RO Spellman MC . The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J. Cutan. Med. Surg.7 (3), 185–192 (2003).
   PubMed Web of Science ®Google Scholar
• Andreassi L Giannetti A Milani M , Scale Investigators G. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br. J. Dermatol.148 (1), 134–138 (2003).
   PubMed Web of Science ®Google Scholar
• Queille-Roussel C . Phase I evaluation of the dermal safety of the fixed combination calcipotriene plus betamethasone dipropionate aerosol foam and foam vehicle. J. Am. Acad. Dermatol.72 (5 Suppl. 1), AB211 (2015).
   Web of Science ®Google Scholar
• Menter A Stein Gl Koo J et al. Fixed combination calcipotriene plus betamethasone dipropionate aerosol foam is well tolerated in patients with psoriasis vulgaris (pooled data from three randomized controlled studies). Skinmed15 (2), 119–124 (2016).
   Google Scholar
• Clinical Trials Database: NCT02899962. https://clinicaltrials.gov/ct2/show/NCT02899962.
   Google Scholar
• Napolitano M Megna M Balato A et al. Systemic treatment of pediatric psoriasis: a review. Dermatol. Ther. (Heidelb.)6 (2), 125–142 (2016).
   PubMed Web of Science ®Google Scholar
• Clinical Trials Database: NCT02387853. https://clinicaltrials.gov/ct2/show/NCT02387853.
   Google Scholar